Is there still a commercial opportunity for CRISPR-Cas9 therapies? A perspective

First it was off-target editing, then concerns about market potential mounted. Now, a new safety signal has investors fleeing the CRISPR gene editing field once again. As fresh worries pile onto old, a central question looms: Is there still a commercial opportunity for the “conventional” CRISPR-Cas9 gene editing therapies that were poised to change the world?

I think there may be, but it’s no longer obvious where that opportunity lies...